<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159637">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01741194</url>
  </required_header>
  <id_info>
    <org_study_id>AC-12-010</org_study_id>
    <nct_id>NCT01741194</nct_id>
  </id_info>
  <brief_title>AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext</brief_title>
  <acronym>NOURISH AD</acronym>
  <official_title>A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Accera, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Accera, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of
      daily living, resource utilization, quality of life, pharmacokinetic measures and safety
      among participants with mild to moderate Alzheimer's Disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(-) participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)</measure>
    <time_frame>8 and 17 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(-) participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clock Draw Interpretation Scale (CDIS)</measure>
    <time_frame>8 and 17 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(-) participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Co-operative Study - Clinical Global Impression of Change (ADCS-CGIC)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(-) participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Co-operative Study - Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(-) participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Alzheimer's Disease (QoL-AD)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(-) participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization in Dementia (RUD-Lite)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(-) participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All participants</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(+) participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Clock Draw Interpretation Scale (CDIS)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(+) participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Alzheimer's Disease Co-operative Study - Clinical Global Impression of Change (ADCS-CGIC)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(+) participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Alzheimer's Disease Co-operative Study - Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(+) participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life - Alzheimer's Disease (QoL- AD)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(+) participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Resource Utilization in Dementia (RUD-Lite)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(+) participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Mini Mental State Exam (MMSE)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>APOE(+) participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>All participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Alzheimer's Disease Co-operative Study - Clinical Global Impression of Change (ADCS-CGIC)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>All participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Alzheimer's Disease Co-operative Study - Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>All participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life - Alzheimer's Disease (QoL - AD)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>All participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Resource Utilization in Dementia (RUD-Lite)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>All participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Clock Draw Interpretation Scale (CDIS)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>All participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Ketone body levels (BHB)</measure>
    <time_frame>baseline, 8, 17 and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>All participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Mini Mental State Exam (MMSE)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>All participants</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>AC-1204</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder formulation (40 g) mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed.  Each dosing unit of AC-1204 contains 20 g of the active ingredient, caprylic triglyceride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is an isocaloric formulation prepared to be virtually identical to AC-1204 in appearance, odor and taste.  Powdered formulation is mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-1204</intervention_name>
    <description>AC-1204 taken once daily, by mouth</description>
    <arm_group_label>AC-1204</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo taken once daily, by mouth</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dementia status of mild to moderate

          -  CT or MRI scan within 18 months prior to screening compatible with a diagnosis of
             probable Alzheimer's disease

          -  Score on the Wechsler Memory Scale - Logical Memory II recall below a pre-determined
             cut-off, adjusted for education level

          -  Confirmed apolipoprotein E genotype prior to randomization

          -  Prior and current use of medication that corresponds with protocol requirements

          -  Stable medical condition, with the exception of dementia, for at least 3 consecutive
             months prior to screening

          -  No active suicidal thoughts within 6 months of screening, no active history of
             suicide attempt in the previous 2 years, no more than 1 lifetime suicide attempt, no
             serious suicidal risk

          -  Able to comply with protocol testing and procedures for the duration of the study

          -  Has a permanent caregiver (caregiver is not expected to change during the course of
             the study) who is willing to attend all visits, oversee the participant's compliance
             with protocol procedures and study medication administration, and report on the
             participant's status

          -  Resides in the community (includes assisted living facilities, but excludes long-term
             care nursing facilities)

          -  Both participant and caregiver have the ability to read and write in English or
             Spanish and have hearing, vision and physical abilities adequate to perform the
             assessments (corrective aids allowed)

          -  Participant and caregiver have provided full written informed consent prior to the
             performance of any protocol-specified procedure.  If participant is unable to provide
             informed consent due to cognitive status, provision of informed consent by
             cognitively intact legally acceptable representative (where this is in accordance
             with local laws, regulations and ethics committee policy)

          -  Participant is able to ingest oral medication

        Exclusion Criteria:

          -  Current use, or use within 3 months of baseline, of medium-chain
             triglyceride-containing products

          -  Use of any other investigational agent within 60 days prior to screening

          -  Known allergy or hypersensitivity to milk or soy products

          -  In the opinion of the investigator, presence or history of advanced, severe,
             progressive or unstable disease of any type that could interfere with protocol
             assessments or put the participant at particular risk

          -  Any medical or neurological condition other than Alzheimer's disease that could
             explain the patient's dementia

          -  History or clinical laboratory evidence of moderate congestive heart failure

          -  Clinically significant ECG abnormalities at screening

          -  History of new cardiovascular events within 6 months prior to baseline

          -  History of or current psychiatric illness

          -  Major depression as determined by Cornell Scale for Depression in Dementia

          -  Insulin-dependent diabetics

          -  Systolic blood pressure &gt; 165 mmHg or diastolic blood pressure  &gt; 95 mmHg

          -  Drop of 20 mm Hg systolic blood pressure or greater upon standing upright from a
             seated position within 3 minutes at screening

          -  Clinically significant anemia at screening

          -  Clinically significant renal disease or insufficiency at screening

          -  Laboratory values for liver function tests &gt; 2.5 times the upper limit of normal at
             screening or history of severe liver disease

          -  Fasting triglycerides &gt; 2.5 times the upper limit of normal at screening

          -  Clinically significant B12 deficiency within 12 month prior to screening

          -  Inflammatory bowel disease or peptic ulcer disease.

          -  Participants with current or a history of (within the last 5 years) complicated
             reflux disease or severe GERD that is not well-controlled by medication.

          -  Irritable bowel syndrome, diverticular disease (e.g., diverticulosis or
             diverticulitis), or chronic gastritis (exclusionary if there has been a diagnosis or
             an acute event within 5 years prior to Screening.)

          -  Has donated ≥ 2 units of blood within the 2 months prior to screening

          -  History of alcohol or drug abuse within 6 months prior to screening, or positive
             urine drug test at screening

          -  Participant or caregiver is an immediate family member or employee of the clinical
             site, sponsor or sponsor's agents

          -  An alternative cause for dementia other than Alzheimer's disease as determined by a
             required CT or MRI scan within 18 months prior to screening

          -  History of neoplasm or malignancies within 5 years prior to screening, except for
             basal cell or squamous cell carcinoma of the skin

          -  Clinically significant hypothyroidism as determined thyroid function testing at
             screening

          -  Participant has scheduled or expected hospitalization and/or surgery during the
             course of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>66 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel T Henderson, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Accera, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet Vogel</last_name>
    <phone>303.999-3703</phone>
    <email>jvogel@accerapharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabrina Greer</last_name>
    <phone>303.999.3743</phone>
    <email>sgreer@accerapharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HOPE Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-288-4673</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Gitt, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-839-6967</phone>
    </contact>
    <investigator>
      <last_name>Allison Perrin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Principals Research Group</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>501-321-0547</phone>
    </contact>
    <investigator>
      <last_name>Gordon Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>501-227-6179</phone>
    </contact>
    <investigator>
      <last_name>Victor Biton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Research LLC</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-858-7448</phone>
    </contact>
    <investigator>
      <last_name>John Murphy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ATP Clinical Research, Inc.</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-277-4472</phone>
    </contact>
    <investigator>
      <last_name>Gustavo Alva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diligent Clinical Trials</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>562-622-0700</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth Zarate-Rowell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Comprehensive Alzheimer's Program</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-246-1378</phone>
    </contact>
    <investigator>
      <last_name>Michael Rafii, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Senior Clinical Trials, Inc.</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>949-588-0909</phone>
    </contact>
    <investigator>
      <last_name>Robert Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>866-787-4257</phone>
    </contact>
    <investigator>
      <last_name>Omid Omidvar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-278-3647</phone>
    </contact>
    <investigator>
      <last_name>Ildiko Kovacs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>619-294-4302</phone>
    </contact>
    <investigator>
      <last_name>Stephen Thein, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-542-3008</phone>
    </contact>
    <investigator>
      <last_name>John Duffy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Research Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Redwood Research Medical Group</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>707-521-3814</phone>
    </contact>
    <investigator>
      <last_name>Allan Bernstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alpine Clinical Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>303-443-7229</phone>
    </contact>
    <investigator>
      <last_name>Paul Brownstone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research, LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-419-4420</phone>
    </contact>
    <investigator>
      <last_name>Joseph Soufer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridian Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>352-597-8839</phone>
    </contact>
    <investigator>
      <last_name>Kelli Maw, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-374-8461</phone>
    </contact>
    <investigator>
      <last_name>Mark Brody, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Southwest Florida</name>
      <address>
        <city>Fort Meyers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>954-455-5757</phone>
    </contact>
    <investigator>
      <last_name>Beth Safirstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Research and Treatment Center</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-209-2400</phone>
    </contact>
    <investigator>
      <last_name>David Watson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Jewish Health Systems</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-514-8503</phone>
    </contact>
    <investigator>
      <last_name>Marc Agronin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-426-9299</phone>
    </contact>
    <investigator>
      <last_name>Eva-Marie Heurich, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Roskamp Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>941-256-8018</phone>
    </contact>
    <investigator>
      <last_name>Andrew Keegan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Axiom Clinical Research of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>813-353-9613</phone>
    </contact>
    <investigator>
      <last_name>Susan Steen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>813-971-8311</phone>
    </contact>
    <investigator>
      <last_name>Mary Stedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-845-0500</phone>
    </contact>
    <investigator>
      <last_name>Carl Sadowsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research, Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>404-851-9934</phone>
    </contact>
    <investigator>
      <last_name>Matthews Gwynn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IU Health Partners Adult Neurology Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-963-7402</phone>
    </contact>
    <investigator>
      <last_name>Martin Farlow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lake Charles Clinical Trials</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70629</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>337-564-6405</phone>
    </contact>
    <investigator>
      <last_name>Kashinath Yadalam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharmasite Research, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>410-602-1440</phone>
    </contact>
    <investigator>
      <last_name>Robert Lehman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimers Disease Center, Quincy Medical Center</name>
      <address>
        <city>Somerville</city>
        <state>Massachusetts</state>
        <zip>02145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-639-5006</phone>
    </contact>
    <investigator>
      <last_name>Anil Nair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Springfield Neurology Associates</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>413-781-5045</phone>
    </contact>
    <investigator>
      <last_name>Michael Rossen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Borgess Research Institute</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>269-226-4803</phone>
    </contact>
    <investigator>
      <last_name>Phillip Green, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Medical School /Department of Neurology &amp; Psychiatry</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>341-977-4811</phone>
    </contact>
    <investigator>
      <last_name>George Grossberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>702-483-6030</phone>
    </contact>
    <investigator>
      <last_name>Charles Bernick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Research</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>856-753-7335</phone>
      <phone_ext>319</phone_ext>
    </contact>
    <investigator>
      <last_name>David Hassman, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Research Corporation</name>
      <address>
        <city>Manchester</city>
        <state>New Jersey</state>
        <zip>08759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>732-657-6100</phone>
    </contact>
    <investigator>
      <last_name>Joseph Shua-Haim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cognitive Research Center of New Jersey</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>908-522-5713</phone>
    </contact>
    <investigator>
      <last_name>Michelle Papka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memory Enhancement Center of NJ</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>732-341-9500</phone>
    </contact>
    <investigator>
      <last_name>Sanjiv Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SPRI Clinical Trials, LLC</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>718-616-2400</phone>
    </contact>
    <investigator>
      <last_name>Nick Vatakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrative Clinical Trials, LLC</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>718-444-7774</phone>
    </contact>
    <investigator>
      <last_name>Inna Yuryev-Golger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parker Jewish Institute For Health Care &amp; Rehabilitation</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>718-289-2103</phone>
    </contact>
    <investigator>
      <last_name>Cornelius Foley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastside Comprehensive Medical Center, LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-288-0138</phone>
    </contact>
    <investigator>
      <last_name>Ram Shrivastava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center Comprehensive Center on Brain Aging</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-263-0770</phone>
    </contact>
    <investigator>
      <last_name>James Galvin, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nathan S. Kline Institute Geriatric Psychiatry Program</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>845-398-5579</phone>
    </contact>
    <investigator>
      <last_name>Nunzio Pomara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ani Neurology, PLLC dba Alzheimer's Memory Ctr</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>704-364-4000</phone>
      <phone_ext>225</phone_ext>
    </contact>
    <investigator>
      <last_name>Mohammad Bolouri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuro-Behavioral Clinical Research, Inc.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>330-493-1118</phone>
    </contact>
    <investigator>
      <last_name>Shishuka Malhotra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Medical Research</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>937-208-8282</phone>
    </contact>
    <investigator>
      <last_name>Meenakshi Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>513-272-9739</phone>
    </contact>
    <investigator>
      <last_name>Alfredo Rivera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-235-8188</phone>
    </contact>
    <investigator>
      <last_name>Louise Thurman, MD, MPh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Research Network (Oregon) Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-279-8252</phone>
    </contact>
    <investigator>
      <last_name>Scott Losk, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-957-9250</phone>
    </contact>
    <investigator>
      <last_name>David Weisman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drexel Neurological Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-762-7090</phone>
    </contact>
    <investigator>
      <last_name>Carol Lippa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurology Clinic, P.C.</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>901-866-9252</phone>
    </contact>
    <investigator>
      <last_name>Thomas Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-577-4017</phone>
    </contact>
    <investigator>
      <last_name>Alex Slandzicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>901-843-1045</phone>
    </contact>
    <investigator>
      <last_name>Lora McGill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Senior Adults Specialty Research, Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>512-407-8628</phone>
    </contact>
    <investigator>
      <last_name>Jaron Winston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Neurology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-798-4734</phone>
      <phone_ext>opt 2</phone_ext>
    </contact>
    <investigator>
      <last_name>Rachelle Doody, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>702-483-6030</phone>
    </contact>
    <investigator>
      <last_name>James Wood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Richmond, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound-Alzhemier's Disease Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>206-277-3965</phone>
    </contact>
    <investigator>
      <last_name>Elaine Peskind, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.AD-Trial.com</url>
    <description>Alzheimer's Survey</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 1, 2014</lastchanged_date>
  <firstreceived_date>November 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
